Sarepta tumbles premarket following gene therapy-linked fatalities

Shares of Sarepta Therapeutics SRPT.O down ~7% at $12.39 in premarket trading on Tuesday

Co said on Monday it will pause all shipments of its Duchenne muscular dystrophy treatment, Elevidys, in the U.S.

A 51-year-old man enrolled in an early-stage study of one of its gene therapies, SRP-9004, died from acute liver failure last week

SRP-9004 is a different investigational therapy from Elevidys but uses a similar gene technology

This marks the third death this year for Sarepta, following the deaths of two teenage boys who had received Elevidys earlier this year

All shipments of Elevidys for Duchenne muscular dystrophy will be temporarily paused by close of business on Tuesday, Sarepta said Monday

Separately, the Children's Hospital Los Angeles said on Monday it has paused usage of Elevidys in all patients with muscular dystrophy